Impel Pharmaceuticals Inc., along with its affiliate, filed a motion for joint administration of their Chapter 11 bankruptcy cases in the US Bankruptcy Court on December 19, 2023. As per the motion, the debtor seeks the joint administration of the cases of its affiliate, Impel NeuroPharma Australia Pty Ltd, with its own case for administrative and procedural purposes. Impel Pharmaceuticals Inc. has been proposed as the lead debtor.
IPI Legacy Liquidation Co
Equities
IMPL
US45258K1097
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.015 USD | 0.00% | 0.00% | -87.85% |
Apr. 12 | North American Morning Briefing : Big Banks Kick -2- | DJ |
Apr. 05 | North American Morning Briefing : Investors on -2- | DJ |
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- IMPL Stock
- News IPI Legacy Liquidation Co
- Motion for Joint Administration Filed by Impel Pharmaceuticals Inc.